Novo Nordisk A/S
A Principal Scientist at Novo Nordisk leads translational studies in cellular and molecular mechanisms underlying type 2 diabetes and its complications. This role involves orchestrating experimental and computational biology approaches to bridge human patient data with preclinical models for early-stage drug discovery.
Headquarters
Alle, Central Jutland, Denmark
Company Size
10001+ employees
Founded
1923
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, with the stated purpose of driving change to defeat diabetes and other serious chronic diseases. It researches, develops, manufactures and markets pharmaceutical products and medical devices across diabetes care, obesity, haemophilia, growth disorders and other endocrine conditions, and is widely known for its insulin and GLP‑1 therapies. Combining extensive R&D, large‑scale manufacturing and global commercial reach, Novo Nordisk emphasizes patient‑centred care, access programs and sustainability in its work to improve outcomes for people with chronic disease.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Novo Nordisk A/S.
5% below the average for this role
Post-Doctoral Fellow, Research
Shirley Ryan AbilityLab
Research Fellow - Joslin Diabetes Center
Beth Israel Lahey Health
Research Fellow
Charterhouse
Senior Director, Translational and Biomarker Lead
Merck & Co., Inc.
Post Doctoral Scholar
The Ohio State University
Scientist II, Biomarker Sciences/Translational Sciences
Revolution Medicines